David Murdoch1. 1. Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand.
Abstract
INTRODUCTION: Up to half of people who ascend to heights above 2500 m may develop acute mountain sickness, pulmonary oedema, or cerebral oedema, with the risk being greater at higher altitudes, and with faster rates of ascent. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent, and to treat, acute mountain sickness? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 17 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: acetazolamide, descent versus resting, dexamethasone, gingko biloba, and slow ascent.
INTRODUCTION: Up to half of people who ascend to heights above 2500 m may develop acute mountain sickness, pulmonary oedema, or cerebral oedema, with the risk being greater at higher altitudes, and with faster rates of ascent. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent, and to treat, acute mountain sickness? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 17 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: acetazolamide, descent versus resting, dexamethasone, gingko biloba, and slow ascent.
Authors: Wei-Fong Kao; Chien-Chun Kuo; Teh-Fu Hsu; Hsing Chang; Ying-Ying Sung; David H T Yen; Jer-Kan Wu; Chen-Hsen Lee Journal: Aviat Space Environ Med Date: 2002-04
Authors: Buddha Basnyat; Jeffrey H Gertsch; E William Johnson; Franco Castro-Marin; Yoshio Inoue; Clement Yeh Journal: High Alt Med Biol Date: 2003 Impact factor: 1.981
Authors: Guy Leadbetter; Linda E Keyes; Kirsten M Maakestad; Sheryl Olson; Martha C Tissot van Patot; Peter H Hackett Journal: Wilderness Environ Med Date: 2009 Impact factor: 1.518
Authors: Martha C Tissot van Patot; Guy Leadbetter; Linda E Keyes; Kirsten M Maakestad; Sheryl Olson; Peter H Hackett Journal: High Alt Med Biol Date: 2008 Impact factor: 1.981